Pancreatic Ductal Adenocarcinoma (PDAC) Stromal Reprogramming Consortium (PSRC) (U01 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for U01 Research Projects to form the NCI-led PDAC Stromal Reprogramming Consortium (PSRC). The overarching objective of the PSRC is to develop a comprehensive understanding of PDAC tumor progression, its microenvironment (TME) as a tumor fate determinant and the reciprocal tumor-TME interactions that drive clinical outcomes. The information obtained through these comprehensive studies should expose new biology-backed vulnerabilities that will inform the development and preclinical testing of novel interventions in PDAC. Central to the PSRC structural organization is the implementation of multidisciplinary team science approaches that iteratively bridge basic and translational research across the tumor-TME continuum in each U01 Research Project, in trans-PSRC activities, and in collaboration with other NCI-funded mechanisms and programs whenever possible.

Companion FOA: RFA-CA-21-042 , U24 Resource-Related Research Project (Cooperative Agreements)


  • Letter of Intent Due Date(s): 30 days prior to the application due date.

  • Application: Nov. 1, 2021

RFA-CA-21-041 Expiration Date: November 02, 2021

Agency Website



Amount Description

Application budgets for each U01 may not exceed $600K in direct costs per year and need to reflect the actual needs of the proposed project.

Applicants may request up to 5 years of support.

Funding Type





Medical - Basic Science
Medical - Clinical Science

External Deadline

November 1, 2021